Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals focuses on the development of innovative treatments in areas such as the central nervous system, immunology, infectious diseases, and rare diseases. The company is involved in advancing scientific programs and has a pipeline of investigational new drugs and biologics, including FDA-approved products for acute migraine.

COM:TONIXPHARMA

Tonix Pharmaceuticals

Last Close

0.20

22/11 21:00

Market Cap

35.51M

Beta: -

Volume Today

30.00M

Avg: -

Financials Not Available